Abstract
The aggregation of tau protein into paired helical filaments is one of the hallmarks of Alzheimers disease and related dementias. We therefore continue our search for non-toxic, cell penetrating inhibitors of tau aggregation, which hold potential for brain penetration. Pickhardt et al. (2005) have reported a high throughput screen for tau aggregation inhibitors previously, which resulted in the identification of several hit classes. Here we report the identification of novel inhibitors which were not present in the initial high throughput assay. This was achieved by transformation of the high throughput screen data into the 3D relationships of virtual pharmacophores The pharmacophore models were utilized in a virtual screen of a Maybridge database. The virtual screen provided 136 hits; 19 representative hits were selected and assayed, this resulted in two novel leads with an IC50 < 13 μM. These two leads feature a novel scaffold for tau aggregation inhibitors.
Keywords: Alzheimer's disease, inhibitors, molecular modeling, protein aggregation, tau protein
Current Alzheimer Research
Title: Screening for Inhibitors of Tau Protein Aggregation into Alzheimer Paired Helical Filaments: A Ligand Based Approach Results in Successful Scaffold Hopping
Volume: 4 Issue: 3
Author(s): Gregor Larbig, Marcus Pickhardt, David G. Lloyd, Boris Schmidt and Eckhard Mandelkow
Affiliation:
Keywords: Alzheimer's disease, inhibitors, molecular modeling, protein aggregation, tau protein
Abstract: The aggregation of tau protein into paired helical filaments is one of the hallmarks of Alzheimers disease and related dementias. We therefore continue our search for non-toxic, cell penetrating inhibitors of tau aggregation, which hold potential for brain penetration. Pickhardt et al. (2005) have reported a high throughput screen for tau aggregation inhibitors previously, which resulted in the identification of several hit classes. Here we report the identification of novel inhibitors which were not present in the initial high throughput assay. This was achieved by transformation of the high throughput screen data into the 3D relationships of virtual pharmacophores The pharmacophore models were utilized in a virtual screen of a Maybridge database. The virtual screen provided 136 hits; 19 representative hits were selected and assayed, this resulted in two novel leads with an IC50 < 13 μM. These two leads feature a novel scaffold for tau aggregation inhibitors.
Export Options
About this article
Cite this article as:
Gregor Larbig , Marcus Pickhardt , David G. Lloyd , Boris Schmidt and Eckhard Mandelkow , Screening for Inhibitors of Tau Protein Aggregation into Alzheimer Paired Helical Filaments: A Ligand Based Approach Results in Successful Scaffold Hopping, Current Alzheimer Research 2007; 4 (3) . https://dx.doi.org/10.2174/156720507781077250
DOI https://dx.doi.org/10.2174/156720507781077250 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Current Topics in Medicinal Chemistry The Implications of Autophagy in Alzheimer’s Disease
Current Alzheimer Research Misfolded Proteins and Human Diseases
Protein & Peptide Letters Traumatic Brain Injury as a Risk Factor for Alzheimer’s Disease: Is Inflammatory Signaling a Key Player?
Current Alzheimer Research Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Translational Methods for Non-Invasive Electrical Stimulation to Facilitate Gait Rehabilitation Following Stroke - The Future Directions
Neuroscience and Biomedical Engineering (Discontinued) Targeting the PAC1 Receptor for Neurological and Metabolic Disorders
Current Topics in Medicinal Chemistry The Correlations between Postmortem Brain Pathologies and Cognitive Dysfunction in Aging and Alzheimer's Disease
Current Alzheimer Research Effects of Snake Venom Polypeptides on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Early Features in Frontotemporal Dementia
Current Alzheimer Research Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science